This contract expires in 124 days (Feb 28, 2027).
LEIDOS BIOMEDICAL RESEARCH INC - NIAID COVID-19 ACTIV3
Key Details
Description
NIAID COVID-19 ACTIV3
Context & Analysis
On Sep 1, 2020, Department of Health and Human Services obligated $159,121,570 to LEIDOS BIOMEDICAL RESEARCH INC for niaid covid-19 activ3. The award is classified under NAICS 541715 — RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT NANOTECHNOLOGY AND BIOTECHNOLOGY). Competition extent: full and open competition. Performance is located in FREDERICK, MD. The contract is scheduled through Feb 28, 2027 — approximately 4 months remaining. This award is one of several similar procurements from Department of Health and Human Services under NAICS 541715 — related awards are listed below.
Market context
- Recompete outlook
- Ends Feb 28, 2027, in 4 months. Recompete signal as of Oct 25, 2026: 85/100, combining time to the end date, the incumbent's history with this agency, whether the award was competed, and its size.
- Competition
- Competed. 85% of 511 awards in this market (Department of Health and Human Services awards in NAICS 541715 over the last 3 years) were competed; median 2 offers.
- Award size
- At $159.1M, this award is larger than 19 in 20 of the 541 priced Department of Health and Human Services awards in NAICS 541715 over the last 3 years (median $1.5M).
- Incumbent at this agency
- LEIDOS BIOMEDICAL RESEARCH INC has 69 other awards from Department of Health and Human Services, totalling $2.8B, 2016–2026.
- Largest vendors in this market
By obligations, Department of Health and Human Services awards in NAICS 541715 over the last 3 years.
- LEIDOS HOLDINGS, INC. — 59 awards, $2.3B
- THE MITRE CORPORATION — 40 awards, $315.7M
- WESTAT, INC. — 11 awards, $222.2M
- BATTELLE MEMORIAL INSTITUTE — 3 awards, $121.5M
- DUKE UNIVERSITY — 16 awards, $117.6M
Computed from USAspending award data on Oct 25, 2026.
Contractor Information
Similar Awards
NCI OPERATIONAL TASK ORDER, FY26-FY27
LEIDOS BIOMEDICAL RESEARCH INC
$826.0M
NCI OPERATIONAL TASK ORDER, FY26-FY27
LEIDOS BIOMEDICAL RESEARCH INC
$327.1M
MD NET
LEIDOS BIOMEDICAL RESEARCH INC
$181.4M
MD NET
LEIDOS BIOMEDICAL RESEARCH INC
$163.5M
ADVANCE UNIVERSAL INFLUENZA VACCINE - FLU MOSAIC VERSION 2 (FLUMOSV2)
LEIDOS BIOMEDICAL RESEARCH INC
$141.7M
Stay Updated
Get notified about new opportunities matching your interests.